In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The 2MACE score predicts cardiovascular events in real-world patients with atrial fibrillation: The FANTASIIA registry.

Session Poster session 6

Speaker Maria Asuncion Esteve Pastor

Event : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Poster Session

Authors : MA Esteve Pastor (Murcia,ES), J Perez-Copete (Murcia,ES), JM Rivera-Caravaca (Murcia,ES), V Roldan (Murcia,ES), I Roldan Rabadan (Madrid,ES), J Muniz (A Coruna,ES), A Cequier (Barcelona,ES), V Bertomeu-Martinez (Alicante,ES), L Badimon (Barcelona,ES), P Rana Miguez (A Coruna,ES), M Anguita (Cordoba,ES), GYH Lip (Birmingham,GB), F Marin (Murcia,ES)

M.A. Esteve Pastor1 , J. Perez-Copete1 , J.M. Rivera-Caravaca2 , V. Roldan2 , I. Roldan Rabadan3 , J. Muniz4 , A. Cequier5 , V. Bertomeu-Martinez6 , L. Badimon7 , P. Rana Miguez4 , M. Anguita8 , G.Y.H. Lip9 , F. Marin1 , 1Hospital Clínico Univeristario Virgen de la Arrixaca, Dept. of Cardiology - Murcia - Spain , 2University Hospital Morales Meseguer, Dept. of Hematology and Clinical Oncology - Murcia - Spain , 3University Hospital La Paz, Dept. of Cardiology - Madrid - Spain , 4Instituto Universitario de Ciencias de la Salud - A Coruna - Spain , 5University Hospital of Bellvitge, Dept. of Cardiology - Barcelona - Spain , 6University Hospital San Juan de Alicante, Dept. of Cardiology - Alicante - Spain , 7Cardiovascular Research Center (CSIC-ICCC) - Barcelona - Spain , 8University Hospital Reina Sofia, Dept. of Cardiology - Cordoba - Spain , 9Birmingham City Hospital, Institute of Cardiovascular Sciences - Birmingham - United Kingdom ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 1126-1127

Background: Atrial Fibrillation (AF) is not only associated with an increased risk of stroke, but also with greater risk of organ damage and cardiovascular (CV) outcomes. The 2MACE score [2 points for Metabolic Syndrome and Age ≥75, and 1 point for Myocardial Infarction/revascularization, Congestive heart failure (ejection fraction ≤40%) and thromboembolism (stroke/TIA)] has been described to help cardiovascular risk in non-valvular AF patients.

Purpose: To investigate the incidence of CV events in a “real world” prospective cohort of AF patients included in the FANTASIIA registry. Second, to validate the 2MACE score as predictor of major adverse cardiovascular events (MACEs).

Methods: We analyzed anticoagulated AF patients who were prospectively recruited into the multicentre FANTASIIA registry. Patients were treated with oral anticoagulation with vitamin K antagonists or direct oral anticoagulants, at least 6 months prior to inclusion. We studied CV risk factors and history of vascular disease. Annual incidence of thromboembolic, MACE (composite of nonfatal MI/revascularization, HF and cardiovascular death) and mortality were recorded.

Results: We studied 1,937 patients (55.7% male, mean 73.8±9.4 years). Dyslipidaemia was the most prevalent risk factor (85.9%) followed by hypertension (80.5%), diabetes (29.2%) and metabolic syndrome (54.1%). After a year of follow-up, there were 60 MACE, 84 patients died (35 of CV causes) and 15 patients with stroke. Patients with 2MACE score ≥3 had higher rates of stroke, thromboembolism, total mortality, cardiovascular mortality and MACE compared to 2MACE score<3. A 2MACE score ≥3 was significantly associated with MACE (HR 3.66, 95% CI 2.16–6.22; p<0.001). The predictive performance of 2MACE according to the ROC curve (c-statistic) was 0.676 (CI 0.608–0.745).

Conclusion: In “real world” AF patients, we observed a high risk of cardiovascular events and mortality in AF patients, relative to stroke and embolic complications. The 2MACE score is a good predictor of MACE and a 2MACE score ≥3 can categorize patients at “high risk”, in identifying patients at risk of MACE.

Cardiovascular eventsGLOBAL Population2MACE <32MACE ≥3P value
(%/year), n=1,937(%/year), n=1,327(%/year), n=610
Myocardial infarction1.080.560.520.11
Total mortality4.331.912.42<0.001
Cardiovascular mortality1.810.521.29<0.001

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are